Skip to content
value.today

Iambic Therapeutics, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2019

Formerly Entos, Inc.

Total raised
$269 M
4 rounds on record
Latest round
$28 M
Apr 2026
First round on record
Sep 2023
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Iambic Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$28 MNo. 4$10 to $50 million

Iambic Therapeutics, Inc.: Raise no. 4, Apr 2026

Investors in this round

7 investors had bought by the notice of Apr 8, 2026: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Iambic Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $50 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fred Manby · Executive Officer, Director
  • Michael Secora · Executive Officer
  • Neil Josephson · Executive Officer
  • Pete Olson · Executive Officer
  • Thomas Miller · Executive Officer, Director
  • Evan Rachlin · Director
  • Jishnu Bhattacharjee · Director
  • Kurt von Emster · Director
  • Mary Tagliaferri · Director
  • R. Jacob Vogelstein · Director
  • Shalini Sharp · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Miller, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 8, 2026. Read the notice at the SEC.

equitySEC
Nov 2025$99 MNo. 3$50 to $250 million

Iambic Therapeutics, Inc.: Raise no. 3, Nov 2025

Investors in this round

22 investors had bought by the notice of Nov 21, 2025: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Iambic Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$99 M of $125 M offered; $26 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fred Manby · Executive Officer, Director
  • Michael Secora · Executive Officer
  • Neil Josephson · Executive Officer
  • Pete Olson · Executive Officer
  • Thomas Miller · Executive Officer, Director
  • Evan Rachlin · Director
  • Jishnu Bhattacharjee · Director
  • Kurt von Emster · Director
  • Mary Tagliaferri · Director
  • R. Jacob Vogelstein · Director
  • Shalini Sharp · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Miller, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 21, 2025. Read the notice at the SEC.

equitySEC
Apr 2024$38 MNo. 2$10 to $50 million

Iambic Therapeutics, Inc.: Raise no. 2, Apr 2024

Investors in this round

11 investors had bought by the notice of Jun 6, 2024: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Iambic Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $50 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fred Manby · Executive Officer, Director
  • Neil Josephson · Executive Officer
  • Tabbert Teng · Executive Officer
  • Thomas Miller · Executive Officer, Director
  • Evan Rachlin · Director
  • Jishnu Bhattacharjee · Director
  • Kurt von Emster · Director
  • R. Jacob Vogelstein · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Miller, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Jun 6, 2024. Read the notice at the SEC.

equitySEC
Sep 2023$103 MNo. 1$50 to $250 million

Iambic Therapeutics, Inc.: Raise no. 1, Sep 2023

Investors in this round

18 investors had bought by the notice of Oct 12, 2023: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Iambic Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$103 M of $110 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chao Zhang · Executive Officer
  • Fred Manby · Executive Officer, Director
  • Tabbert Teng · Executive Officer
  • Thomas Miller · Executive Officer, Director
  • Evan Rachlin · Director
  • Jishnu Bhattacharjee · Director
  • Kurt von Emster · Director
  • R. Jacob Vogelstein · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Miller, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Iambic Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).

    SEC Form D · Apr 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2026

That is all the official record says: Iambic Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Iambic Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
ARK Venture FundFund or asset manager$13 Mheldnot statedHolds shares (fund report, Jul 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Iambic Therapeutics, Inc.
NameRoleNamed in
Fred ManbyExecutive officerApr 2026
Michael SecoraExecutive officerApr 2026
Neil JosephsonExecutive officerApr 2026
Pete OlsonExecutive officerApr 2026
Thomas MillerExecutive officerApr 2026
Tabbert TengExecutive officerJun 2024
Chao ZhangExecutive officerOct 2023
Evan RachlinDirectorApr 2026
Fred ManbyDirectorApr 2026
Jishnu BhattacharjeeDirectorApr 2026
Kurt von EmsterDirectorApr 2026
Mary TagliaferriDirectorApr 2026
R. Jacob VogelsteinDirectorApr 2026
Shalini SharpDirectorApr 2026
Thomas MillerDirectorApr 2026
William RastetterDirectorApr 2026